Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Untch

Showing results (141-150 of 377) with videos related to

Pageof 38
Sort By:
European Journal of Cancer (Oxford, England : 1990)|June 29, 2021
Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapyFrederik Marmé, Christine Solbach, Laura Michel, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|October 14, 2019
Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: Results from the phase III BrighTNess trialMehra Golshan, Stephanie M Wong, Sibylle Loibl, et al.
Geburtshilfe Und Frauenheilkunde|July 2, 2025
Treatment of Patients with Early Breast Cancer: 19th St. Gallen International Breast Cancer Consensus Discussed against the Background of German Treatment RecommendationsMichael Untch, Maggie Banys-Paluchowski, Sara Y Brucker, et al.
Geburtshilfe Und Frauenheilkunde|March 16, 2026
Correction: Treatment of Patients with Early Breast Cancer: 19th St. Gallen International Breast Cancer Consensus Discussed against the Background of German Treatment RecommendationsMichael Untch, Maggie Banys-Paluchowski, Sara Y Brucker, et al.
Breast Cancer Research and Treatment|June 26, 2015
Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trialsSibylle Loibl, Christian Jackisch, Bianca Lederer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2012
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypesGunter von Minckwitz, Michael Untch, Jens-Uwe Blohmer, et al.
JAMA Surgery|January 9, 2020
Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical TrialMehra Golshan, Sibylle Loibl, Stephanie M Wong, et al.
Breast Care (Basel, Switzerland)|February 26, 2019
Validation of a Nomogram Predicting Non-Sentinel Lymph Node Metastases among Patients with Breast Cancer after Primary Systemic Therapy - a transSENTINA SubstudyCornelia Liedtke, Dennis Görlich, Ingo Bauerfeind, et al.
European Journal of Cancer (Oxford, England : 1990)|March 19, 2022
Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patientsMarion T van Mackelenbergh, Fenja Seither, Volker Möbus, et al.
The Lancet. Oncology|January 20, 2012
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trialMichael Untch, Sibylle Loibl, Joachim Bischoff, et al.
Pageof 38

Showing results (141-150 of 377) with videos related to

Sort By:
Pageof 38
European Journal of Cancer (Oxford, England : 1990)|June 29, 2021
Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapyFrederik Marmé, Christine Solbach, Laura Michel, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|October 14, 2019
Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: Results from the phase III BrighTNess trialMehra Golshan, Stephanie M Wong, Sibylle Loibl, et al.
Geburtshilfe Und Frauenheilkunde|July 2, 2025
Treatment of Patients with Early Breast Cancer: 19th St. Gallen International Breast Cancer Consensus Discussed against the Background of German Treatment RecommendationsMichael Untch, Maggie Banys-Paluchowski, Sara Y Brucker, et al.
Geburtshilfe Und Frauenheilkunde|March 16, 2026
Correction: Treatment of Patients with Early Breast Cancer: 19th St. Gallen International Breast Cancer Consensus Discussed against the Background of German Treatment RecommendationsMichael Untch, Maggie Banys-Paluchowski, Sara Y Brucker, et al.
Breast Cancer Research and Treatment|June 26, 2015
Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trialsSibylle Loibl, Christian Jackisch, Bianca Lederer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2012
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypesGunter von Minckwitz, Michael Untch, Jens-Uwe Blohmer, et al.
JAMA Surgery|January 9, 2020
Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical TrialMehra Golshan, Sibylle Loibl, Stephanie M Wong, et al.
Breast Care (Basel, Switzerland)|February 26, 2019
Validation of a Nomogram Predicting Non-Sentinel Lymph Node Metastases among Patients with Breast Cancer after Primary Systemic Therapy - a transSENTINA SubstudyCornelia Liedtke, Dennis Görlich, Ingo Bauerfeind, et al.
European Journal of Cancer (Oxford, England : 1990)|March 19, 2022
Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patientsMarion T van Mackelenbergh, Fenja Seither, Volker Möbus, et al.
The Lancet. Oncology|January 20, 2012
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trialMichael Untch, Sibylle Loibl, Joachim Bischoff, et al.
Pageof 38